ID   K562-s
AC   CVCL_UC15
DR   ATCC; CRL-3343
DR   Wikidata; Q94335726
RX   PubMed=10910924;
CC   Population: Caucasian.
CC   Characteristics: Clone of K-562 used as a control cell line for studies using K562-s which is resistant to imatinib.
CC   Doubling time: ~24-30 hours (ATCC=CRL-3343).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 29-06-23; Version: 10
//
RX   PubMed=10910924; DOI=10.1182/blood.V96.3.1070;
RA   Mahon F.-X., Deininger M.W.N., Schultheis B., Chabrol J., Reiffers J.,
RA   Goldman J.M., Vaz de Melo J.;
RT   "Selection and characterization of BCR-ABL positive cell lines with
RT   differential sensitivity to the tyrosine kinase inhibitor STI571:
RT   diverse mechanisms of resistance.";
RL   Blood 96:1070-1079(2000).
//